ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.60099
0.00%
Brent Oil
84.10
0.60%
Bitcoin
67,109.72
1.44%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. ArQule Inc (ARQL)

  7. ArQule Inc (ARQL) Noticias

ARQL

ArQule (ARQL)

ArQule Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ARQL
FechaHoraFuenteTítuloSímboloCompañía
14/02/202016:35Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARQLArQule Inc
14/02/202011:20Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ARQLArQule Inc
27/01/202012:55Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:ARQLArQule Inc
21/01/202005:00Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ARQLArQule Inc
06/01/202010:07PR Newswire (US)Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the FirmNASDAQ:ARQLArQule Inc
12/12/201914:49PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc.NASDAQ:ARQLArQule Inc
10/12/201902:02Dow Jones NewsMerck, Sanofi Push To Add Cancer Drugs -- WSJNASDAQ:ARQLArQule Inc
09/12/201918:16Dow Jones NewsBig Drugmakers Push Deeper Into Cancer Treatment -- 4th UpdateNASDAQ:ARQLArQule Inc
09/12/201915:37Dow Jones NewsBig Drugmakers Push Deeper Into Cancer Treatment -- 3rd UpdateNASDAQ:ARQLArQule Inc
09/12/201914:12Dow Jones NewsU.S. Stocks Slip as Trade War Weighs on Chinese ExportsNASDAQ:ARQLArQule Inc
09/12/201913:33Dow Jones NewsBig Drugmakers Push Deeper Into Cancer Treatment -- 2nd UpdateNASDAQ:ARQLArQule Inc
09/12/201910:13Dow Jones NewsMerck to Buy ArQule for $2.7 Billion -- UpdateNASDAQ:ARQLArQule Inc
09/12/201907:05Business WireArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology...NASDAQ:ARQLArQule Inc
09/12/201906:37PR Newswire (US)(ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price?NASDAQ:ARQLArQule Inc
09/12/201906:26Dow Jones NewsMerck to Buy ArQule for $2.7 Billion, or $20/ShareNASDAQ:ARQLArQule Inc
09/12/201905:45Business WireMerck to Acquire ArQule, Advancing Leadership in OncologyNASDAQ:ARQLArQule Inc
25/11/201906:00Business WireArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual ...NASDAQ:ARQLArQule Inc
13/11/201906:00Business WireArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019NASDAQ:ARQLArQule Inc
06/11/201908:05Business WireArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversi...NASDAQ:ARQLArQule Inc
30/10/201909:57Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ARQLArQule Inc
30/10/201906:30Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARQLArQule Inc
30/10/201906:00Business WireArQule Reports Third Quarter 2019 Financial ResultsNASDAQ:ARQLArQule Inc
29/10/201915:01Business WireArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets & Cancer Ther...NASDAQ:ARQLArQule Inc
21/10/201906:00Business WireArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformati...NASDAQ:ARQLArQule Inc
16/10/201906:00Business WireArQule to Report Third Quarter 2019 Financial Results on October 30, 2019NASDAQ:ARQLArQule Inc
16/10/201906:00Business WireArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets & Cancer T...NASDAQ:ARQLArQule Inc
08/10/201906:00Business Wire ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society ...NASDAQ:ARQLArQule Inc
02/10/201906:00Business WireArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome & PI...NASDAQ:ARQLArQule Inc
26/09/201906:00Business WireArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019NASDAQ:ARQLArQule Inc
25/09/201909:41Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARQLArQule Inc
 Showing the most relevant articles for your search:NASDAQ:ARQL

Su Consulta Reciente

BIT
F27010
Vontobel Financial Produ...
USOTC
LBLCF
Loblaw Companies (PK)
USOTC
LGYSF
Ling Yue Services (PK)
NYSE
ASZ
Austerlitz Acquisition C...
BOV
BBIL39
Jpmorgan Betabuilders In...
BIT
I06772
Intesa Sanpaolo
NASDAQ
TBLA
Taboola com
LSE
WTMA
AMEX
BMAY
Innovator US Equity Buff...
COIN
SANDGGBP
BSTP
IMXUSD
Immutable X
LSE
73LI
Higher Ed.1 B2s
COIN
DRACEUR
ASX
VRX
VRX Silica
USOTC
RRSES
RSE Archive (GM)
USOTC
MDEVF
Melco Intl Dev (PK)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados